BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05718557 (PYX106 in advanced solid tumors): BVCT ex-ante prediction vs. reported outcome

On 9 Apr 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 19 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically probably insignificant and commercially probably insufficient.

Clinical Trial

NCTID
NCT05718557
Drug Name
PYX106
Drug MoA
anti-SIGLEC-15 inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
advanced solid tumors
Human Patients
60
Sponsor
Pyxis Oncology
Phase
Phase 1

Prediction of , index 1485

Prospective Prediction
Prediction Index
1485
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak clinical benefit in PFS/OS/ORR)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
254 days in advance
Readout Data Interpretation
PYX106 is safe yet probably ineffective (no ORR data disclosed for 45 patients) and its further development discontinued
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably insignificant and commercially probably insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors
Phase
Phase 1
Status
Active not recruiting
Enrollment
47
Lead sponsor
Pyxis Oncology, Inc
Conditions
Solid Tumor
Interventions
DRUG: PYX-106
Design
Single group · None
Primary purpose
Treatment
Start
2023-05-23
Primary completion
2026-05
Completion
2026-05
Primary outcomes
  • Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) (Day 1 to Day 28)
  • Number of Participants Who Experience an Adverse Event (AE) (Day 1 up to approximately 19 months)

NCT05718557 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials